EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) has announced its participation in several upcoming conferences aimed at improving the lives of patients with serious eye disorders.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) has announced its participation in several upcoming conferences aimed at improving the lives of patients with serious eye disorders. The company will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022, at 7:00 a.m. ET, and at the Baird 2022 Global Healthcare Conference on September 14, 2022, at 1:25 p.m. ET. Additionally, a Fireside Chat at the Guggenheim Nantucket Therapeutics Conference is scheduled for September 29, 2022, at 10:30 a.m. ET, followed by another on September 30, 2022, at 11:40 a.m. ET during the Benzinga Retail Conference.
Details
News Market Reaction – EYPT
The recorded move for EYPT in the trading session of this news was +3.62%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WATERTOWN, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced that EyePoint Pharmaceuticals will present at the following upcoming conferences:
- H.C. Wainwright 24th Annual Global Investment Conference
Forum: Corporate Presentation
Date: Monday, September 12, 2022
Time: 7:00 a.m. ET
- Baird 2022 Global Healthcare Conference
Forum: Corporate Presentation
Date: Wednesday, September 14, 2022
Time: 1:25 p.m. ET
- Guggenheim Nantucket Therapeutics Conference
Forum: Fireside Chat
Date: Thursday, September 29, 2022
Time: 10:30 a.m. ET
- Benzinga Retail Conference (Virtual)
Forum: Fireside Chat
Date: Friday, September 30, 2022
Time: 11:40 a.m. ET
A webcast and subsequent archived replay of the corporate presentation may be accessed via the Investors section of the Company website at www.eyepointpharma.com.
About EyePoint Pharmaceuticals
EyePoint Pharmaceuticals (Nasdaq: EYPT) is a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. The Company's pipeline leverages its proprietary Durasert® technology for sustained intraocular drug delivery including EYP-1901, an investigational sustained delivery intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration. The proven Durasert drug delivery platform has been safely administered to thousands of patients' eyes across four U.S. FDA approved products, including YUTIQ® for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, which is currently marketed by the Company. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.
Investors:
Christina Tartaglia
Stern IR
Direct: 212-698-8700
christina.tartaglia@sternir.com
Media Contact
Amy Phillips
Green Room Communications
Direct: 412-327-9499
aphillips@greenroompr.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.